Investigating the tissue migration of anti-MRSA drugs in soft tissue infections
Not Applicable
- Conditions
- Pressure ulcer in sacral and ischial region which have been performed flap reconstruction.
- Registration Number
- JPRN-UMIN000036933
- Lead Sponsor
- Saitama Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients aged under 15 years or over 100 years.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The concentration of the anti MRSA medicine in the tissue fluid, the blood plasma and tissue transitivity of the medicine, We compare the concentration using the fluid in the drainage bag and the data of blood test until 3days post operation date.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence tissue migration of anti-MRSA drugs in sacral/ischial pressure ulcers post-flap reconstruction?
How does tissue penetration of anti-MRSA drugs compare to standard-of-care antibiotics in post-flap reconstruction soft tissue infections?
Which biomarkers predict optimal drug distribution in flap-reconstructed pressure ulcers with MRSA colonization?
What adverse events are associated with anti-MRSA drug tissue migration in complex wound healing scenarios?
Are combination therapies with anti-MRSA drugs enhancing tissue migration in biofilm-associated soft tissue infections?